Moberg Pharma appoints Torbjörn Wärnheim, Director Pharmaceutical Innovation and Development, as a member of Moberg’s Management Team.
Wärnheim has had this position at Moberg Pharma since 2013. Prior to his position with Moberg, Torbjörn Wärnheim was Vice President R&D at Fresenius Kabi. In addition to this he has held senior level positions at ACO HUD and Pharmacia & Upjohn among others. Torbjörn Wärnheim has a broad experience of pharmaceutical development of Rx- and OTC-products, and is associate professor at Royal Institute of Technology (KTH), Stockholm, with a research background within surface chemistry and physical chemistry of lipids.
“It is a pleasure to welcome Torbjörn Wärnheim to the Management Team at Moberg. I look forward to keep working together to continue to progress our development programs,” says Peter Wolpert, CEO of Moberg Pharma AB.